Advanced

Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation

Luksch, R.; Tienghi, A.; Hall, K. Sundby; Fagioli, F.; Picci, P.; Barbieri, E.; Gandola, L.; Eriksson, Mikael LU ; Ruggieri, P. and Daolio, P., et al. (2012) In Annals of Oncology 23(11). p.2970-2976
Abstract
The Italian Sarcoma Group and the Scandinavian Sarcoma Group designed a joint study to improve the prognosis for patients with Ewing's family tumors and synchronous metastatic disease limited to the lungs, or the pleura, or a single bone. The study was opened in 1999 and closed to the enrollment in 2008. The program consisted of intensive five-drug combination chemotherapy, surgery and/or radiotherapy as local treatment, and consolidation treatment with high-dose busulfan/melphalan plus autologous stem cell rescue and total-lung irradiation. During the study period, 102 consecutive patients were enrolled. The median follow-up was 62 months (range 24-124). The 5-year event-free survival probability was 0.43 [standard deviation (SD) = 0.05]... (More)
The Italian Sarcoma Group and the Scandinavian Sarcoma Group designed a joint study to improve the prognosis for patients with Ewing's family tumors and synchronous metastatic disease limited to the lungs, or the pleura, or a single bone. The study was opened in 1999 and closed to the enrollment in 2008. The program consisted of intensive five-drug combination chemotherapy, surgery and/or radiotherapy as local treatment, and consolidation treatment with high-dose busulfan/melphalan plus autologous stem cell rescue and total-lung irradiation. During the study period, 102 consecutive patients were enrolled. The median follow-up was 62 months (range 24-124). The 5-year event-free survival probability was 0.43 [standard deviation (SD) = 0.05] and the 5-year overall survival probability was 0.52 (SD = 0.052). Unfavorable prognostic factors emerging on multivariate analysis were a poor histological/radiological response at the site of the primary tumor [relative risk (RR) = 3.4], and incomplete radiological remission of lung metastases after primary chemotherapy (RR = 2.6). One toxic death and one secondary leukemia were recorded. This intensive approach is feasible and long-term survival is achievable in similar to 50% of patients. New treatment approaches are warranted for patients responding poorly to primary chemotherapy. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Ewing's sarcoma, high-dose chemotherapy, lung metastases, total-lung, irradiation
in
Annals of Oncology
volume
23
issue
11
pages
2970 - 2976
publisher
Oxford University Press
external identifiers
  • wos:000310373100032
  • scopus:84868149746
ISSN
1569-8041
DOI
10.1093/annonc/mds117
language
English
LU publication?
yes
id
795589b6-08a0-427d-a3bc-d15fae6e1bff (old id 3283443)
date added to LUP
2013-01-07 09:41:01
date last changed
2017-10-29 04:02:38
@article{795589b6-08a0-427d-a3bc-d15fae6e1bff,
  abstract     = {The Italian Sarcoma Group and the Scandinavian Sarcoma Group designed a joint study to improve the prognosis for patients with Ewing's family tumors and synchronous metastatic disease limited to the lungs, or the pleura, or a single bone. The study was opened in 1999 and closed to the enrollment in 2008. The program consisted of intensive five-drug combination chemotherapy, surgery and/or radiotherapy as local treatment, and consolidation treatment with high-dose busulfan/melphalan plus autologous stem cell rescue and total-lung irradiation. During the study period, 102 consecutive patients were enrolled. The median follow-up was 62 months (range 24-124). The 5-year event-free survival probability was 0.43 [standard deviation (SD) = 0.05] and the 5-year overall survival probability was 0.52 (SD = 0.052). Unfavorable prognostic factors emerging on multivariate analysis were a poor histological/radiological response at the site of the primary tumor [relative risk (RR) = 3.4], and incomplete radiological remission of lung metastases after primary chemotherapy (RR = 2.6). One toxic death and one secondary leukemia were recorded. This intensive approach is feasible and long-term survival is achievable in similar to 50% of patients. New treatment approaches are warranted for patients responding poorly to primary chemotherapy.},
  author       = {Luksch, R. and Tienghi, A. and Hall, K. Sundby and Fagioli, F. and Picci, P. and Barbieri, E. and Gandola, L. and Eriksson, Mikael and Ruggieri, P. and Daolio, P. and Lindholm, P. and Prete, A. and Bisogno, G. and Tamburini, A. and Grignani, G. and Abate, M. E. and Podda, M. and Smeland, S. and Ferrari, S.},
  issn         = {1569-8041},
  keyword      = {Ewing's sarcoma,high-dose chemotherapy,lung metastases,total-lung,irradiation},
  language     = {eng},
  number       = {11},
  pages        = {2970--2976},
  publisher    = {Oxford University Press},
  series       = {Annals of Oncology},
  title        = {Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation},
  url          = {http://dx.doi.org/10.1093/annonc/mds117},
  volume       = {23},
  year         = {2012},
}